Harpoon Therapeutics Shares Up 9% on Patient Dosing for Blood Cancer Treatment

By Chris Wack

Harpoon Therapeutics Inc. shares rose 9% to $13.51 after the company said that the first patient has been dosed with HPN217 in a phase 1/2 clinical trial focused on a type of blood cancer.

The immunotherapy company said HPN217 aims to treat relapsed, refractory multiple myeloma and is being developed under a global license and option agreement with AbbVie Inc. Dosing of the first patient in a clinical trial has triggered a $50 million milestone payment to Harpoon.

HPN217 targets B-cell maturation antigen, an antigen expressed on malignant multiple myeloma calls. HPN217 is Harpoon's third product candidate to enter the clinic and is based on Harpoon's proprietary Tri-specific T cell Activating Construct platform designed to recruit a patient's own immune cells to destroy tumors.

Harpoon said the first patient was treated at Colorado Blood Cancer Institute and the Sarah Cannon Research Institute at HealthONE's Presbyterian St. Luke's Medical Center.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 27, 2020 12:25 ET (16:25 GMT)

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024